

**Supplementary Table 2 Comparison of clinical data between SLE patients with II/V or III/IV LN(n=120)**

Clinical characteristics	Mean $\pm$ SD / Positive(%)		Nominal P value
	II/V LN (n=33)	III/IV LN (n=87)	
Age	34.79 $\pm$ 2.30	35.62 $\pm$ 1.39	0.846
Sex, male/female	5/28	15/72	0.784
Disease duration, months	1.0 (0.5, 3.0)	1 (0.5, 6.5)	0.154
2019 criteria score without renal biopsy	17.03 $\pm$ 1.10	20.56 $\pm$ 0.64	<b>0.005</b>
Fever	4 (12.12%)	23 (26.44%)	0.4927
Mucocutaneous domain			
Acute cutaneous lupus	14 (42.42%)	27 (31.03%)	0.283
Subacute cutaneous lupus or discord rash	0	1	1
Non-scarring alopecia	6 (18.18%)	10 (11.49%)	0.336
Oral ulcer	3 (9.09%)	3 (3.45%)	0.205
musculoskeletal domain	5 (15.15%)	16 (18.39%)	0.677
Serosal domain	5 (15.15%)	29 (33.33%)	<b>0.048</b>
Neuropsychiatric domain	0	3 (3.45%)	0.560
Hematologic domain			
Leucopenia	11 (33.33%)	23 (26.44%)	0.454
Thrombocytopenia	7 (21.21%)	27 (31.03%)	0.286
Autoimmune haemolysis	2 (6.06%)	6 (6.90%)	0.870
Laboratory criteria			
Anti- $\beta$ 2GP1 antibodies (IgG and/or IgM)	7 (21.21%)	25 (28.74%)	0.405
Anticardiolipin antibodies (IgG and/or IgM)	6 (18.18%)	26 (29.89%)	0.196
Lupus anticoagulan*	0	0	
Complement			
C3	24 (72.73%)	81 (93.10%)	<b>0.0026</b>
C4	22 (66.67%)	72 (82.76%)	0.0561
Anti-dsDNA antibody	6 (18.18%)	62 (71.26%)	<b>&lt;0.0001</b>
Anti-Sm antibody	19 (57.58%)	22 (25.29%)	<b>0.0009</b>

\*The data of lupus anticoagulant was absent.

SLEDAI, SLE disease activity index.